PhaseBio Pharmaceuticals

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods.

PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013.

PhaseBio is based in Malvern, Pennsylvania.

PhaseBio Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Medical, Medical Device sector. The company focuses on Biotechnology and has secured $57.1B in funding across 176 round(s). With a team of 51-100 employees, PhaseBio Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - PhaseBio Pharmaceuticals, raised $25.0M. Discover more about their projects, partnerships, and impact on our platform.